


Monensin

Chemical Properties

CAS No. :	17090-79-8
Formula:	C ₃₆ H ₆₂ O ₁₁
Molecular Weight:	670.87
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Monensin is an orally active natural antibiotic that also functions as an ion carrier mediating Na ⁺ /H ⁺ exchange and a Wnt inhibitor, effective against Gram-positive bacteria, Plasmodium falciparum, and certain viruses.
Targets(IC50)	Antibiotic,Sodium Channel,Wnt/beta-catenin
In vitro	Monensin (1-5 μM; 48 hours) can significantly reduce the viability of SCC9, SCC25, and GM-38 cells in a dose-dependent manner [1]. Monensin (1 or 5 μM; 24 hours) can induce a strong apoptotic response in SCC25 cells [1]. Monensin (0.1 or 1 μM; 24 hours) can inhibit pEGFR and its downstream targets pAKT and pERK in SCC9 and SCC25 cells [1].
In vivo	Monensin (10 mg/kg, administered orally, daily for 6 weeks) can inhibit the progression of intestinal tumors in multiple intestinal neoplasia (Min) mice, with no toxic effects observed on normal intestinal mucosa during the experiment [2].

Solubility Information

Solubility	DMSO: Soluble,Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.4906 mL	7.453 mL	14.906 mL
5 mM	0.2981 mL	1.4906 mL	2.9812 mL
10 mM	0.1491 mL	0.7453 mL	1.4906 mL
50 mM	0.0298 mL	0.1491 mL	0.2981 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. *Mol Cancer Ther.* 2014 Nov;13(11):2559-71.
- Luo Q, Liu Q, Cheng H, et al. Nondegradable ubiquitinated ATG9A organizes Golgi integrity and dynamics upon stresses. *Cell reports.* 2022, 40(7): 111195.
- Ma X, Liang X, Li Y, et al. Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field. *Nature Communications.* 2023, 14(1): 1606.
- Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. *Mol Cancer Ther.* 2014 Apr;13(4):812-22.
- Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. *Front Microbiol.* 2020 Apr 30;11:790.
- Ji Y, Wang A, Zeng W, et al. Secretion correlation between matrix metalloproteinases and extracellular vesicles revealed by synchronized dynamic monitoring of single cells on a microfluidic chip. *Sensors and Actuators B: Chemical.* 2024: 136836.
- Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. *Traffic.* 2005 Feb;6(2):131-43.
- Improving the immunomodulatory function of mesenchymal stem cells by defined chemical approach

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481